News Column

Studies from C.H. Lu et al Have Provided New Data on Immunotherapy (GPC3 expression in mouse ovarian cancer induces GPC3-specific T cell-mediated...

September 8, 2014



Studies from C.H. Lu et al Have Provided New Data on Immunotherapy (GPC3 expression in mouse ovarian cancer induces GPC3-specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth)

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators publish new report on Biotechnology. According to news reporting originating in Nagoya, Japan, by NewsRx journalists, research stated, "Glypican-3 (GPC3) is specifically expressed in ovarian clear cell carcinoma (OCCC), hepatocellular carcinoma (HCC), and melanoma and lung cancer. GPC3 is being explored as a potential candidate for OCCC and HCC immunotherapy."

The news reporters obtained a quote from the research, "As a tumor-associated antigen, induction of immune response of GPC3 in ovarian cancer remains elusive. We established a GPC3 transgenic mouse ovarian cancer cell line, OV2944-HM-1 (HM-1), and used the intraperitoneal ovarian cancer mouse model to investigate immune response in GPC3-expressing tumor. We found that GPC3 expression in the tumor increased F4/80(+)CD86(+) macrophage (M1) proportion and caused GPC3-specific CD8(+)T cell immune responses, and prolonged mouse survival."

According to the news reporters, the research concluded: "Our results demonstrated that GPC3 expression induced T cell-mediated immune response in this mouse ovarian cancer model and also provided supportive evidence that GPC3 is an ideal target for ovarian cancer immunotherapy."

For more information on this research see: GPC3 expression in mouse ovarian cancer induces GPC3-specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. Oncology Reports, 2014;32(3):913-921. Oncology Reports can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Biotechnology).

Our news correspondents report that additional information may be obtained by contacting C.H. Lu, Bell Res Center Reprod Hlth & Canc, Nagoya, Aichi 4580818, Japan. Additional authors for this research include K. Shibata, S. Suzuki, H. Kajiyama, T. Senga, Y. Koya, M. Daimon, M. Yamashita and F. Kikkawa.

Keywords for this news article include: Nagoya, Japan, Asia, Biotechnology, Cancer, Connective Tissue Cells, Immunology, Immunomodulation, Immunotherapy, Macrophages, Mononuclear Phagocyte System, Myeloid Cells, Oncology, Phagocytes, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters